 Whether this means that ezetimibe is of no overall benefit in FH is unknown.There are no interventional studies that directly show mortality benefit of cholesterol lowering in FH.Rather, evidence of benefit is derived from a number of trials conducted in people who have polygenic hypercholesterolemia (in which heredity plays a smaller role).